I Switched GLP-1 Medications — Which Drug and Which Claim Applies?

Marin & MurphySuper Lawyers® 2014–2024(888) 348-2735

Ozempic (GLP-1) Lawsuit — Free Case Review

Your Stomach Symptoms Were Real

If you took brand-name Ozempic, Wegovy, or Rybelsus and were diagnosed with a tested, documented stomach injury with an ER or hospital visit, you may qualify.

No Ozempic or other GLP-1 lawsuit has been settled, and no court or jury has found that these medications caused anyone's injury — the litigation is ongoing, with major expert-evidence rulings still ahead. Whether any individual has a claim depends on their own medical records and the law of their state.

Did this happen to you — or someone you love?

Start your free case reviewTell us anyway

Answered 24/7 · Free & confidential · No fee unless there is a recovery. Court costs and litigation expenses are advanced by counsel and repaid from the recovery. You are not responsible for court costs or litigation expenses if there is no recovery, unless a court directs otherwise. The attorney's fee is a percentage of the gross recovery, calculated before expenses are deducted.

(888) 348-2735

Partners

Matthew T. Marin & Stefanie A. Murphy

Super Lawyers® honorees · American Association for Justice members

Ozempic inquiries get a personal review — and an honest answer either way, free and without obligation.

No Ozempic or other GLP-1 lawsuit has been settled, and no court or jury has found that these medications caused anyone's injury — the litigation is ongoing, with major expert-evidence rulings still ahead. Whether any individual has a claim depends on their own medical records and the law of their state. Do not stop, start, or change any prescribed medication because of anything on this page. Those decisions belong with your prescriber. Attorney Advertising.

Switching between GLP-1 medications does not disqualify anyone, but which brand you were taking matters, and the tracks treat brands differently. NAION vision-loss criteria cover Ozempic, Wegovy, Rybelsus, Trulicity, Mounjaro, and Zepbound. Stomach-injury criteria currently cover only the semaglutide brands — Ozempic, Wegovy, and Rybelsus — and not Mounjaro, Zepbound, or Trulicity. For a switcher, the question is which brand you were taking when the injury was diagnosed — and pharmacy records establish that.

Switching is normal, and the criteria expect it

Plenty of people have taken more than one of these medications. Formularies change, supply ran short, and prescribers moved people between drugs for tolerability, cost, or results. Someone who started on Ozempic in 2022, moved to Mounjaro in 2023, and is on Zepbound today has an ordinary history.

Intake is built around that reality: the questionnaire asks about each medication separately, with its own prescriber, pharmacy, and start and stop dates. You are not being asked to pick one, only to lay out the sequence.

Which brands belong to which track

• NAION (sudden optic-nerve vision loss) — covers brand-name Ozempic, Wegovy, Rybelsus, Trulicity, Mounjaro, and Zepbound. Both manufacturers’ products are in scope, so switching between a Novo Nordisk drug and an Eli Lilly drug does not move you outside the track.
• Stomach injuries (gastroparesis or gastric obstruction) — currently covers only the semaglutide brands: Ozempic, Wegovy, and Rybelsus. Mounjaro, Zepbound, and Trulicity do not qualify for this track as the criteria stand.
• Generic and compounded semaglutide — including product from compounding pharmacies, telehealth services and med spas — does not meet the brand-name requirement in either track today. Criteria differ across programs and they change, so tell us anyway rather than assuming there is nothing to discuss.

That asymmetry is the most important thing for a switcher to understand, and it explains most of the confusion we hear.

What the switch means in practice

For a stomach injury, the question is what you were taking when the diagnosis was made: the criteria require diagnosis while taking the medication or within about 30 days of stopping, and a semaglutide brand. Someone diagnosed with gastroparesis while on Ozempic who later switched to Mounjaro is in a very different position from someone diagnosed while on Mounjaro. Both are worth reviewing.

For NAION, the analysis is simpler, because all six brands are covered and a diagnosis made while taking the medication or after stopping can qualify. The sequence still matters to the case, but is far less likely to decide eligibility.

If your own sequence is unclear — you cannot remember which drug you were on in a given month, or they overlapped — that is not a problem you need to solve before calling. It is what pharmacy records resolve.

Brand documentation: what actually proves it

Memory is unreliable about drug names, and these six brands are easy to mix up. Documentation settles it.

• Pharmacy fill history. The single most useful document. Any retail pharmacy will print one on request, listing drug name, strength, quantity, prescriber and date for every fill. If you used more than one pharmacy, request from each.
• Prescriber records — the chart shows what was prescribed and when.
• Insurance or pharmacy-benefit statements, which independently show fills by drug name.
• Physical items — pens, boxes, cartons, labels, dose counters and packaging inserts.
• Receipts, letters and emails, particularly for anything ordered through a telehealth service — often the only record that a product was compounded rather than brand-name.

For each medication we ask the same questions: brand name; whether it was brand-name, compounded, generic, or you are not sure; the prescribing doctor and pharmacy, with addresses; and the start and stop month and year. “Not sure” is an allowed answer and routes to review, not to a no.

Where the litigation stands

No GLP-1 case has settled and none has been tried. MDL 3094 had 4,025 cases pending as of the October 2026 JPML report, with a Rule 702 hearing held September 14 through 18, 2026; in August 2025 that court ruled a gastroparesis claim must rest on a properly performed gastric emptying study. MDL 3163 was created December 15, 2025, had 247 cases pending, and has issued no merits rulings. European regulators concluded in June 2025 that NAION is a very rare side effect of semaglutide medicines. Both manufacturers dispute causation.

Common questions

Common questions: can you sue?, it’s not about your doctor, still taking Ozempic?, is it too late to file?, still on a GLP-1, stopped taking it, calling for a parent, and how compensation works.